Vanguard Asset Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.19M Buy
129,787
+101,176
+354% +$1.51M ﹤0.01% 1514
2026
Q2
$417K Hold
28,611
– – ﹤0.01% 2254
2026
Q1
$542K Buy
+28,611
New +$463K ﹤0.01% 2055

Other funds holding SMMT

Vanguard Asset Management's SMMT Position: Q3 2026 in Review

Vanguard Asset Management increased its Summit Therapeutics (SMMT) stake by 354% in Q3 2026, buying an estimated $1.51M and bringing the position to 129,787 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Vanguard Asset Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Vanguard Asset Management held 129,787 shares of Summit Therapeutics worth $2.19M as of Q3 2026.
  • Vanguard Asset Management bought 101,176 Summit Therapeutics shares in Q3 2026, an estimated $1.51M.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1514 holding.
  • Vanguard Asset Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.